Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.30    -0.90 (-1.36%)
Bid:
65.30
Ask:
65.70
Spread: 0.40 (0.613%)
Market Cap: £576.88m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Share buyback programme

8 Oct 2021 07:00

RNS Number : 4317O
IP Group PLC
08 October 2021
 

FOR RELEASE ON

08 October 2021

 

 

IP Group plc - Share buyback programme

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that it has today launched a programme to purchase ordinary shares of 2 pence each in IP Group ("Ordinary Shares") up to an aggregate consideration of £35 million (the "Buyback Programme").

 

As previously announced and consistent with its Capital Allocation Policy, the Group's Board has specifically reserved up to £35 million for share buybacks. In light of the Group's prevailing share price, notwithstanding recent portfolio events, and consistent with its commitment to shareholder returns, the Board has determined that now is the appropriate time to formally launch the Buyback Programme.

 

The Group has entered into a non-discretionary arrangement with Numis to manage the Buyback Programme and repurchase Ordinary Shares on its behalf and within certain parameters, including to only buy back Ordinary Shares at a discount to Hard NAV per share. The Buyback Programme will run from the date of this announcement to 31 March 2022, unless terminated earlier. Numis will make its trading decisions in relation to the Ordinary Shares independently of the Group. 

Purchases of Ordinary Shares pursuant to the Buyback Programme will take place in open market transactions and may be made from time-to-time depending on market conditions, the Group's share price, trading volumes in the Group's Ordinary Shares and other factors. The maximum price paid per Ordinary Share will be: (A) no more than the higher of: (i) 5 per cent above the average of the middle market quotations taken from the London Stock Exchange Daily Official List for the five business days preceding any ordinary shares being purchased; and (ii) the price of the last independent trade and the highest independent bid for Ordinary Shares on the trading venue where the purchase is carried out; and (B) no less than (exclusive of expenses) a price of 2 pence per Ordinary Share, being the nominal value of an Ordinary Share. Under the Buyback Programme, any Ordinary Shares purchased will be held in treasury.

The Buyback Programme is in accordance with IP Group's general authority to purchase a maximum of 106,253,373 Ordinary Shares, granted by its shareholders at the Annual General Meeting held on 9 June 2021. The Buyback Programme will also be effected within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), including where relevant pursuant to the Market Abuse (Amendment)(EU Exit) Regulations 2019), and in accordance with Chapter 12 of the Financial Conduct Authority's Listing Rules. IP Group confirms that it currently has no other unpublished price sensitive information.

IP Group will make further regulatory announcements to shareholders in respect of purchases of Ordinary Shares by the Group as they occur.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFDLLBFBLXFBD
Date   Source Headline
26th Jun 202312:41 pmRNSDirector Declaration
15th Jun 20231:19 pmRNSResult of AGM
15th Jun 20237:00 amRNSAGM Statement
8th Jun 20238:51 amRNSLife Sciences update event
7th Jun 202311:00 amRNSIP Group plc - TR1 form
31st May 20232:34 pmRNSTotal Voting Rights
12th May 20231:26 pmRNSDirector Declaration
10th May 202312:11 pmRNSDirector/PDMR Shareholding
3rd May 202310:56 amRNSDirector Declaration
28th Apr 20233:21 pmRNSTotal Voting Rights
20th Apr 20235:00 pmRNSNotice of AGM, Annual Report
18th Apr 20233:23 pmRNSRSP & DBSP awards; Director/PDMR shareholding
15th Mar 20239:31 amRNSInvestor presentation
13th Mar 20239:00 amRNSDirector/PDMR Shareholding
13th Mar 20237:00 amRNSNo direct deposits or credit facilities with SVB
8th Mar 20237:00 amRNSIP Group plc - Annual Results
2nd Mar 20233:25 pmRNSTR-1
21st Feb 20237:00 amRNSAMSL Aero's all-electric aircraft maiden flight
10th Feb 20239:55 amRNSNotice of Results
31st Jan 202310:00 amRNSTotal Voting Rights
30th Jan 20237:00 amRNSStatement re press speculation
24th Jan 20231:18 pmRNSForm 8.3 - Mirriad Advertising plc
18th Jan 20237:00 amRNSDirectorate Change
11th Jan 20237:00 amRNSPortfolio company Oxbotica raises $140m Series C
3rd Jan 202311:48 amRNSTotal Voting Rights
12th Dec 20224:58 pmRNSAGM post-meeting shareholder engagement update
7th Dec 20224:39 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIstesso announces FDA Fast Track for MBS2320
2nd Dec 202211:38 amRNSPortfolio company funding leads to £36m gain
30th Nov 202210:41 amRNSTotal Voting Rights
21st Nov 20222:13 pmRNSLife sciences presentation postponed
2nd Nov 20223:51 pmRNSInvestor presentation on life sciences
1st Nov 20228:59 amRNSNotification of major holdings
31st Oct 20224:35 pmRNSDirector/PDMR Shareholding
27th Oct 20224:55 pmRNSPDMR Dealing – SAYE Exercise
24th Oct 20226:02 pmRNSHolding(s) in Company
14th Oct 20229:42 amRNSHolding(s) in Company
30th Sep 202210:39 amRNSTotal Voting Rights
21st Sep 20225:29 pmRNSHolding(s) in Company
20th Sep 20226:10 pmRNSDirector/PDMR Shareholding
15th Sep 20224:41 pmRNSInvestor presentation
14th Sep 20224:33 pmRNSFurther re Scrip Dividend
13th Sep 20226:00 pmRNSFurther re Interim Scrip Dividend
13th Sep 20227:01 amEQSIP Group Trust (IPO): Initiation — International investor in impactful innovation
7th Sep 20224:33 pmRNSDirector/PDMR Shareholding, SAYE scheme
31st Aug 20228:51 amRNSIstesso starts Phase 2b trial of MBS2320
30th Aug 202212:59 pmRNSCash acquisition of portfolio company Diurnal
18th Aug 20229:25 amRNSScrip Dividend Reference Price
11th Aug 202210:50 amRNSHolding(s) in Company
3rd Aug 20227:00 amRNSHalf-yearly results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.